US WorldMeds, LLC Receives $15 Million Grant to Launch New Study
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOUISVILLE, Ky.--(BUSINESS WIRE)--US WorldMeds has begun enrolling patients in a Phase III clinical trial that will complete the development program for lofexidine hydrochloride (Lofexidine) as a new therapeutic for the treatment of withdrawal symptoms associated with opiate detoxification. The trial was made possible by a three-year $15 million grant from the National Institute on Drug Abuse (NIDA) designed to facilitate progress in Lofexidine’s development toward the next stage in the Food and Drug Administration (FDA) approval process.
Help employers find you! Check out all the jobs and post your resume.
LOUISVILLE, Ky.--(BUSINESS WIRE)--US WorldMeds has begun enrolling patients in a Phase III clinical trial that will complete the development program for lofexidine hydrochloride (Lofexidine) as a new therapeutic for the treatment of withdrawal symptoms associated with opiate detoxification. The trial was made possible by a three-year $15 million grant from the National Institute on Drug Abuse (NIDA) designed to facilitate progress in Lofexidine’s development toward the next stage in the Food and Drug Administration (FDA) approval process.
Help employers find you! Check out all the jobs and post your resume.